匹伐他汀与依折替米贝联合治疗儿童杂合性家族性高胆固醇血症2例。

IF 0.6 Q3 MEDICINE, GENERAL & INTERNAL

Clinical Case Reports Pub Date : 2025-09-29 DOI:10.1002/ccr3.71018

Katsufumi Nishioka, Sonoko Kondo, Kanako Irie, Takeo Kondo, Takashi Iwase, Ryosuke Tani, Tomoko Inoue, Keiji Matsunaga, Tetsuo Minamino, Takashi Kusaka

引用次数: 0

摘要

杂合子家族性高胆固醇血症（HeFH）使个体易患动脉粥样硬化，包括冠状动脉疾病，导致60%未经治疗的病例死于心血管疾病。儿童时期的适当干预是必要的。在日本，只有匹伐他汀被批准用于儿童FH。对他汀类药物的不良反应使治疗具有挑战性；最佳干预可能需要联合治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Two Cases of Heterozygous Familial Hypercholesterolemia in Children Effectively Managed With Pitavastatin and Ezetimibe Combination Therapy

查看原文本刊更多论文

Two Cases of Heterozygous Familial Hypercholesterolemia in Children Effectively Managed With Pitavastatin and Ezetimibe Combination Therapy

Heterozygous familial hypercholesterolemia (HeFH) strongly predisposes individuals to atherosclerosis, including coronary artery disease, leading to death from cardiovascular diseases in > 60% of untreated cases. Appropriate intervention from childhood is necessary. In Japan, only pitavastatin is approved for pediatric FH. A poor response to statins makes treatment challenging; optimal intervention may require combination therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Case Reports MEDICINE, GENERAL & INTERNAL-

自引率

14.30%

发文量

1268

审稿时长

13 weeks

期刊介绍： Clinical Case Reports is different from other case report journals. Our aim is to directly improve global health and increase clinical understanding using case reports to convey important best practice information. We welcome case reports from all areas of Medicine, Nursing, Dentistry, and Veterinary Science and may include: -Any clinical case or procedure which illustrates an important best practice teaching message -Any clinical case or procedure which illustrates the appropriate use of an important clinical guideline or systematic review. As well as: -The management of novel or very uncommon diseases -A common disease presenting in an uncommon way -An uncommon disease masquerading as something more common -Cases which expand understanding of disease pathogenesis -Cases where the teaching point is based on an error -Cases which allow us to re-think established medical lore -Unreported adverse effects of interventions (drug, procedural, or other).